SCHEMBL4057778

SCHEMBL4057778

Clc1ccccc1CCc1nc2ncc(-c3ccco3)cc2[nH]1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NOS3 P29474 3/20 0.44
NOS1 P29475 3/20 0.44
NOS2 P35228 3/20 0.44
KDM4E B2RXH2 2/20 0.40
GAA P10253 2/20 0.40
MAPT P10636 2/20 0.40
MEN1 O00255 2/20 0.40
KMT2A Q03164 2/20 0.40
ALDH1A1 P00352 1/20 0.40
LMNA P02545 1/20 0.40
PLA2G1B P04054 1/20 0.40
POLB P06746 1/20 0.40
HPGD P15428 1/20 0.40
ALOX12 P18054 1/20 0.40
PTPN7 P35236 1/20 0.40
RECQL P46063 1/20 0.40
DUSP3 P51452 1/20 0.40
BLM P54132 1/20 0.40
L3MBTL1 Q9Y468 1/20 0.40
ATG4B Q9Y4P1 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4060153 0.91 KDM4E (0.39) NOS3NOS1NOS2KDM4EGAA
SCHEMBL4055542 0.85 NOS1 (0.51) NOS3NOS1NOS2ALDH1A1LMNA
SCHEMBL4060650 0.85 NOS3 (0.49) NOS3NOS1NOS2MAPTALDH1A1
SCHEMBL4056418 0.85 NOS1 (0.41) NOS3NOS1NOS2MAPTMEN1
SCHEMBL4053237 0.84 NOS3 (0.42) NOS3NOS1NOS2KDM4EMAPT
SCHEMBL4054780 0.83 NOS3 (0.57) NOS3NOS1NOS2MEN1KMT2A
SCHEMBL4058842 0.83 MEN1 (0.41) NOS3NOS1NOS2GAAMAPT
SCHEMBL13608646 0.82 MAPT (0.40) KDM4EGAAMAPTMEN1KMT2A
SCHEMBL4054880 0.80 NOS3 (0.42) NOS3NOS1NOS2KDM4EMAPT
SCHEMBL4058313 0.80 NOS1 (0.44) NOS3NOS1NOS2MAPTMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7622479-B2 Bicyclic derivative, its production and use TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-11-24 US disclosed
US-20050101647-A1 Bicyclic derivative, its production and use TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2005-05-12 US disclosed
EP-1460067-A1 BICYCLIC DERIVATIVE, PROCESS FOR PRODUCING THE SAME, AND USE Takeda Chemical Industries, Ltd. (JP) 2004-09-22 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050101647-A1 Bicyclic derivative, its production and use ABL1, SRC, PTK2B NOS3 907/4885NOS1 879/4885NOS2 1019/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.